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ABSTRACT: The use of computational tools to identify bio-
logical targets of natural products with anticancer properties and
unknown modes of action is gaining momentum. We employed
self-organizing maps to deconvolute the phenotypic effects of
piperlongumine (PL) and establish a link to modulation of the
human transient receptor potential vanilloid 2 (hTRPV2) channel.
The structure of the PL-bound full-length rat TRPV2 channel was
determined by cryo-EM. PL binds to a transient allosteric pocket
responsible for a new mode of anticancer activity against
glioblastoma (GBM) in which hTRPV2 is overexpressed. Calcium
imaging experiments revealed the importance of Arg539 and
Thr522 residues on the antagonistic effect of PL and calcium influx modulation of the TRPV2 channel. Downregulation of hTRPV2
reduces sensitivity to PL and decreases ROS production. Analysis of GBM patient samples associates hTRPV2 overexpression with
tumor grade, disease progression, and poor prognosis. Extensive tumor abrogation and long term survival was achieved in two
murine models of orthotopic GBM by formulating PL in an implantable scaffold/hydrogel for sustained local therapy. Furthermore,
in primary tumor samples derived from GBM patients, we observed a selective reduction of malignant cells in response to PL ex vivo.
Our results establish a broadly applicable strategy, leveraging data-motivated research hypotheses for the discovery of novel means
tackling cancer.
■ INTRODUCTION
Natural products provide ample opportunities to develop
innovative medicines.1−4 However, understanding their mech-
anisms of action remains a bottleneck to unlock their promise
in drug discovery.5−9 Chemoproteomics is a privileged
approach to unveil new biology for molecules of therapeutic
interest. However, such methods are laborious and time-
consuming and unlikely identify membrane proteins and
targets with only minute expression.9 Moreover, chemo-
proteomics relies on structural manipulation of the chemical
entities under study, which may have unpredictable out-
comes.10 Considering the large volume of publicly available
bioactivity data, statistical learning of ligand−target relation-
ships has become tractable in recent years and amenable to
providing probabilistically motivated target binding hypoth-
eses.7,11 One such ligand-based target-identification program
(SPiDER: self-organizing map-based prediction of drug
equivalence relationships)11 has been validated for the
deorphanization of natural products and discovery of new
biology,7,12 drug repurposing,13,14 and the unravelling of
primary and secondary pharmacology.2 Indeed, in silico
technologies are a growing concept in drug discovery that
may offer complementary/alternative solutions for not only
target identification programs7,14 but also discovery chemistry
in general.15
Piperlongumine (PL) is an alkaloid that has attracted much
attention as a selective anticancer agent despite its unclear
pharmacology and mode of action.16−18 Thus, unveiling the
underlying pharmacology can open new research avenues and
leverage the development of PL as an efficacious cancer
treatment. Here, we used SPiDER, as an alternative to
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chemical proteomics, to identify potential biological targets for
PL that could be pursued in downstream validation studies.
We report on an unprecedented link between PL and the
human transient receptor potential vanilloid 2 (hTRPV2)
channel. To achieve this, we performed extensive experimental
validationincluding cryoelectron microscopy (cryo-EM)
to illuminate the PL−TRPV2 molecular recognition mecha-
nism. Our studies reveal a new, transient binding site in
TRPV2, whose recognition results in selective, potent allosteric
antagonism by PL. Moreover, we found that the anticancer
activity of PL is high in cell lines with high hTRPV2
expression, which is a marker of poor prognosis in glioblastoma
multiforme (GBM). Most importantly, local (intracranial) and
sustained delivery of PL in mice with GBM using a bespoke
material produced a potent and selective antitumor effect and
almost complete remission of the disease. Additionally, we
observed a selective reduction of malignant cells in response to
PL ex vivo in primary tumor samples derived from GBM
patients. These results open up new vistas for successful GBM
therapies.
■ RESULTS AND DISCUSSION
Self-Organizing Maps Identify TRP Channels as
Targets of Piperlongumine. We used the SPiDER
method7,13 that employs self-organizing maps and topological
descriptors to infer biological targets for small molecules. By
correlating PL to the structure of reference ligands, targets
were predicted (Table S1). We prioritized TRP channels for
screening given the high prediction confidence and availability
of assays for panel screening. Moreover, a privileged link
Figure 1. SPiDER identifies piperlongumine as a selective, reversible, and allosteric antagonist of human TRPV2 (hTRPV2). (a) Manifold learning
(t-distributed stochastic neighborhood embedding) of transient receptor potential (TRP) channel ligand data as described by CATS2 descriptors.
PL (black dot) presents an uncommon pharmacophore among known TRP ligands as it is located in a region of low ligand density. (b) PL is a
selective hTRPV2 antagonist. ControlshTRPV2, tranilast (IC50 = 2.3 μM ± 0.25 log units); hTRPA1, ruthenium red (IC50 = 2.3 μM ± 0.19 log
units); hTRPC7, SKF 96365 (IC50 = 103 μM ± 0.27 log units); n = 2. (c) Inhibition of cannabidiol (CBD, 4 μM) evoked calcium influx by PL (5
μM) in hTRPV2-transfected HEK293T cells. For quantification, only the strongest responding cells were analyzed (n = 30−40 cells). Shaded
regions correspond to the 95% confidence interval of the mean response. ****p < 0.0001 (DMSO versus PL; DMSO versus nontransfected; one-
way ANOVA, Dunnett post hoc test) at 300 s poststimulation. (d) Concentration−response curve of PL against hTRPV2 with a patch-clamp assay.
IC50 = 1 μM ± 0.52 log units, n = 2, stimulus: 4 μM CBD. (e) Exemplary patch-clamp time-course trace that shows the inhibitory effect of PL (100
μM) against the CBD-activated (4 μM) hTRPV2 currents; n = 2. Data are consistent with reversible binding. (f) Normalized responses of the drug
wash-out experiment. Data are consistent with reversible binding. (g) EC50 plots for CBD with increasing concentrations of PL. (h) Michaelis−
Menten plots of CBD/PL coincubation. Decreasing EC50 and vmax values are consistent with allosteric inhibition by PL.
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between several members of the TRP channel family and
natural products had been established.2,8,19,20 We further
motivated screening of PL against TRP channels by processing
the SPiDER output with a data visualization algorithm. PL was
projected onto a region of low TRP ligand density, which
suggests that its pharmacophore has been scarcely employed to
interrogate TRP-channel biology as opposed to molecules
within other regions of chemical space (Figure 1a).
To validate the drug-target prediction, we tested PL in
functional, cell-based fluorescence assays. PL showed antago-
nism of hTRPV2 (IC50 = 4.6 μM ± 0.13 log units) and
selectivity against a TRP channel panel (Figure 1b). Agonistic
activity was not detected in any case. In calcium-imaging
experiments with HEK293T cells transiently transfected with
hTRPV2-RFP, we confirmed significant inhibition (p < 0.0001;
one-way ANOVA and Dunnett post hoc test) of calcium influx
evoked by cannabidiolan hTRPV2 agonist (Figure 1c).
Figure 2. PL binding pocket revealed by cryo-EM. Cryo-EM map of PL-bound TRPV2 (a) and a close up of the PL-binding site (b). A single
monomer is colored purple while the others are gray; lipids are colored khaki, and density for PL is colored orange. (c, d) Cartoon and stick
representation of the PL binding site from two different angles, with TRPV2 represented in purple and PL in orange. Effect of PL (5 μM) on
cannabidiol (CBD, 4 μM) induced calcium influx in HEK293T cells, transfected with hTRPV2-RFP and variants (R539A and T522M). (e)
Inhibitory potential of piperlongumine in cells transfected with hTRPV2-RFP and variants (R539A and T522M), measured by calcium imaging.
For quantification, 40−60 responding cells were analyzed in each well (n = 3), and values were normalized to the baseline. One-way ANOVA of
significant difference between the control (NT cells) and other represented groups: p < 0.0001 (****), p > 0.05 (n.s.). Values represent mean ±
SEM. (f) Bar graph of peaks at 260 s poststimulation. Two-way ANOVA for multiple comparisons between groups: p < 0.0001 (****), p > 0.05
(n.s.).
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Similarly, PL inhibited calcium influx evoked by cannabidiol
(IC50 = 1 μM ± 0.52 log units; Figure 1d, Figure S1) in a
patch-clamp assay. The Michael acceptor motifs in PL have
been previously implicated in covalent and irreversible
modification of proteins.18 To confirm that PL reversibly
inhibits hTRPV2, we performed wash-out assays. The
functional hTRPV2 activity could be reinstated, which shows
that binding is either noncovalent or that PL presents a fast off-
rate after covalent modification of hTRPV2 (Figure 1e,f). This
observation contrasts with a recent report on the covalent and
stable modification of GSTO1 by PL.21 We next synthesized
two PL analogues, as a racemic mixture, comprising a
cyclopropane ring and without Michael acceptor motifs. The
trans derivative displayed a perfect alignment with that of PL
(Figure S2). No functional activity was found for both small
molecules (Figure S3), suggesting a potential role of the
conjugated motifs for molecular recognition, namely, for
inducing a bioactive conformation. To further understand
modulation of TRPV2 by PL, we probed whether PL and
cannabidiol compete for the same binding pocket through a
series of coincubation experiments. The maximal effect and
apparent vmax value of cannabidiol decreased with increasing
PL concentrations (Figure 1g,h). Both observations are
consistent with noncompetitive (allosteric) antagonism.22
Neither autofluorescence nor SCAM behavior23 that could
interfere with assay readouts was detected at relevant assay
concentrations (Table S2).
Molecular Mechanism of Piperlongumine Interaction
with TRPV2. We used cryo-EM to gain atomistic insight into
the molecular mechanism of TRPV2 antagonism by PL. We
reconstituted the full-length rat TRPV2 (rTRPV2, 77%
identity and 90% similarity to hTRPV2) into nanodiscs and
incubated with 50 μM PL (≈10 times the EC50) before
preparing grids for cryo-EM. This yielded an rTRPV2−PL
complex data set with a single state at 3.5 Å with C4 symmetry
(Table S3 and Figures S4 and S5). This state was similar to the
apo truncated rabbit TRPV2 in amphipols (PDB 5AN8) and
the cannabidiol (CBD) state 2 rTRPV2 in nanodisc (PDB
6U88) (Figure 2a, Figures S4 and S5) structures determined
previously.24−27 The reconstructed map has the highest quality
in the transmembrane region, but no density is resolved for the
pore turret (residues Ser564−Pro587).
Recent structures of rTRPV2 in nanodiscs show density for
lipid tails in the vanilloid pocket;25 these densities are absent in
the PL-bound cryo-EM map (Figure S6). Instead, we observed
an elongated density starting at the vanilloid pocket and
stretching along the top of the S4−S5 linker that we have
attributed to PL. This density is wedged above the S4−S5
linker in a pocket formed by the S4 helix and the S5 and S6
helices of an adjacent TRPV2 monomer (Figure 2b, Figure
S6). The trimethoxylphenyl moiety in PL is oriented toward
the C-terminal end of the S4−S5 linker and the vanilloid
pocket, whereas the dihydropyridinone group is oriented
toward the N-terminal end (Figure 2c). PL is stabilized in this
new allosteric pocket by hydrogen bridges between the two
carbonyl groups of PL and the side-chains of Thr522 and
Arg539 (Figure 2d). A density similar to that of PL is not
Figure 3. Conformational changes to TRPV2 on PL binding. (a) Ion permeation pathway of PL-bound TRPV2. Two opposing monomers are
depicted as cartoons; gray dots represent open volume along the ion permeation pathway. (b) Pore profile of PL-bound TRPV2 (purple) and apo
TRPV2 (PDB 6U84) (pink). The radius of a dehydrated calcium ion (1.1 Å) is depicted as a dashed black line. Cartoon representations of PL-
bound TRPV2 (purple) and apo TRPV2 (PDV 6U84) showing shifts around the S4−S5 linker (c) and overall structural changes (d).
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Figure 4. hTRPV2 expression is required by CNS cancer cell lines and associated with disease progression and poor prognosis in glioblastoma
multiforme. (a) Cell lines with high hTRPV2 expression (as defined in Figure S12a) are sensitive to PL activity (−AUC). **** represents p <
0.0001 (Wilcoxon rank-sum test). (b) Cell lines from the Central Nervous System (CNS) lineage are the most sensitive to hTRPV2 loss. The effect
of hTRPV2 loss-of-function was quantified with the CERES dependency score: a lower score represents a higher likelihood that the gene is essential
in a given cell line. Left: smoothed histogram of distribution of hTRPV2 dependency scores across all cell lines. (c) hTRPV2 expression is a marker
for poor prognosis in human gliomas. Overall survival Kaplan−Meier plots for patient stratification based on hTRPV2 median expression in low-
and high-grade gliomas. p values for log-rank tests for differences in survival are shown. (d) hTRPV2 expression increases concomitantly with brain
tumor stage. hTRPV2 expression across GTEx normal and TCGA tumor (grouped in LGG grade II, LGG grade III, and GBM) brain samples.
Black points and lines represent the median ± upper/lower quartiles. ** represents p < 0.01 and **** p < 0.0001 (Wilcoxon rank sum test). (e)
qRT-PCR of hTRPV2 in matched primary and recurrent GBM pairs. PGK1 was used as an internal control, and the Wilcoxon matched pairs signed
rank test was used for statistics. (f) hTRPV2 is expressed in endothelial and microglia/macrophage brain tumor cells. hTRPV2 expression (log2 of
counts per million, CPM) across 3589 single cells derived from four GBM human samples, grouped by cell type. Data are shown as mean ±
standard error. (g) hTRPV2 is expressed in diffuse human gliomas, in glial (white arrowhead) and in endothelial cells (black arrowhead); and
endothelial cells in GBM display an intense and diffuse staining of the cytoplasmic membrane in areas of microvascular proliferation, which
contrasts with the weak or negative staining of the endothelial cells of grade II and III gliomas, and with the cytoplasmic and punctate staining
pattern of glial cells.
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present in any currently published TRPV2 X-ray or cryo-EM
map24−28 (Figure S6).
rTRPV2 Arg539 (Arg537 in humans) is conserved as either
Arg or Lys across the TRPV family in humans. Thus, while it
may be involved in PL recognition, it is unlikely to account for
TRPV2 selectivity. Moreover, Thr522 (Thr520 in humans) is
highly conserved across TRPV2 in different species but is not
conserved across the TRPV family in humans (Figure S7).
While the Thr520/522 position is also a Thr in human
TRPV4, it is a Met in TRPV3 and the otherwise highly
homologous TRPV1 (Figure S7). Altogether, this may make
Thr520/522 key for PL specificity. To challenge this
hypothesis, validate the binding site, and test the contribution
of these two residues to the effect of PL, we mutated Arg539 to
Ala and Thr522 to Met in hTRPV2 and measured changes in
calcium uptake. In calcium-imaging experiments using the wild
type hTRPV2, we reconfirmed inhibition of calcium influx by
PL (p ≤ 0.0001; two-way ANOVA) when cannabidiol was
evoked (Figure 2e,f, Figures S8−S10). The Arg539Ala
mutation showed a loss of inhibition by PL (p ≤ 0.0001;
two-way ANOVA), consistent with its predicted role as a PL
binding site. More interestingly, the Thr522Met mutation not
only showed a loss of inhibition by PL (p ≤ 0.0001; two-way
ANOVA) but also overall increased calcium uptake both with
and without the addition of PL. It is not possible to determine
from these experiments whether this increase in calcium uptake
was due to increased hTRPV2 expression and/or trafficking to
the cell membrane or because the Thr520Met mutation
increased channel activity in response to CBD. The
Thr520Met mutation not only alters hydrogen bridging
possibilities but also introduces a bulkier residue that could
restrict access of PL to the binding site. Taken together, our
data highlight the relevance of these two residues in the
antagonism of TRPV2 by PL with changes in calcium influx.
Structurally, PL induces conformational changes in the
TRPV2 selectivity filter and lower gate. Both remain closed
when PL is bound; the conformation of the lower gate shifts
slightly downward, and His651 rotates out of the pore relative
to the recently published apo rat TRPV2 in nanodisc structure
(PDB 6U84) (Figures 3a,b). The downward shift in the PL-
bound structure seems to originate at the S4−S5 linker, which
shifts toward S5 by 4.0 Å and downward by 2.9 Å, with the
adjacent helices, including S6, shifting to compensate (Figure
3c). The shift of the S4−S5 linker toward S5 is reminiscent of
the changes seen in the recent structure of rTRPV2 bound to
CBD, state 2 (PDB 6U88) (Figure S11), though that structure
did not have the additional downward shift of the S4−S5 linker
seen in the PL-bound structure. On top of this, the PL-bound
structure has the C-terminal domain wrapped around its β-
sheet region paired with a downward pivot of the intracellular
ankyrin repeat domains (Figure 3d), again as seen in the CBD
state 2 structure (PDB 6U88) (Figure S11). Overall, the entire
molecule shifts downward by 2.8 Å relative to the central pore,
creating a transient allosteric tunnel where PL sits (Figure 3d).
The transmembrane domain of the PL-bound structure also
aligns well to the apo truncated rabbit TRPV2 structure, which
was predicted to be desensitized27 (Figure S11). Taken
together, these changes suggest that PL may inhibit TRPV2
by immobilizing the S4−S5 linker and locking TRPV2 in a
desensitized state.
hTRPV2 Expression Is Required by CNS Cancer Cell
Lines and Associated with Disease Progression and
Poor Prognosis in GBM. To probe the role of hTRPV2 on
the antiproliferative effects of PL, we screened PL against the
NCI-60 panel of cancer cell lines29 and analyzed the publicly
available CTRP data.30 In both panels, cell lines expressing
hTRPV2 were very sensitive to PL (Wilcoxon rank-sum test p
< 0.0001 and 0.005, respectively, for the CTRP and NCI-60
panels; Figure 4a, Figures S12−S14), supporting the
importance of hTRPV2 modulation as a mechanism that
contributes to the anticancer activity by PL. To identify cancer
types potentially more vulnerable to hTRPV2 targeting, we
analyzed CRISPR-Cas9 hTRPV2 loss-of-function screens
performed in 764 cancer cell lines within the Cancer
Dependency Map (DepMap).31 Cell lines from the central
nervous system (CNS) were the most sensitive to hTRPV2
loss (Figure 4b, Figure S15), suggesting CNS tumors as
candidate disease models for hTRPV2 targeting.
To further investigate the importance of hTRPV2 in
different cancer types, we tested its prognostic value across
9785 tumor samples belonging to 30 cohorts from The Cancer
Genome Atlas (TCGA; Table S4). High hTRPV2 expression is
strongly associated with poor survival in patients with gliomas
(p = 4.37 × 10−13, log-rank test; Figure S16), also when
stratified into the low-grade glioma (LGG)32 and GBM33
cohorts individually (p = 0.028 and 0.0087, respectively, log-
rank test; Figure 4c). The prognostic value of hTRPV2 was
independently validated in two other cohorts of gliomas and
GBMs from the Chinese Glioma Genome Atlas (CGGA,
http://www.cgga.org.cn/; Figure S17). We also found a
significant progressive increase of hTRPV2 expression with
tumor grade (Figure 4d) and from primary to matched
recurrent GBM samples (Figure 4e). These results thus
associate hTRPV2 overexpression with worse outcome in
GBM.
We next analyzed the transcriptomes of human GBM single
cells34 and found hTRPV2 expressed predominantly in
endothelial and microglia/macrophage tumor cells but not in
neoplastic tumor cells (Figure 4f, Figure S18) or normal brain
samples35 (Figure S19). Concordantly, hTRPV2 expression is
negatively associated with tumor purity, i.e., with the number
of neoplastic cells vs non-neoplastic cells present in the LGG
and GBM samples (Spearman’s correlation coefficient, ρ =
−0.45 and −0.36, p = 7.5 × 10−25 and 3.1 × 10−14,
respectively; Figure S20), showing that hTRPV2 is mainly
expressed in the tumor microenvironment. This was validated
in selected samples from patients diagnosed with grade II−IV
glioma, where immunostaining for hTRPV2 showed expression
in glial and endothelial cells (Figure 4g, Figure S21). Most
significantly, in areas of microvascular proliferation, a
characteristic pathologic feature of GBM, endothelial cells
showed a significant overexpression of hTRPV2 (Figure S22),
and a distinct staining distribution/pattern (Figure 4g). In glial
cells, staining was cytoplasmic and with a punctate pattern,
whereas endothelial cells showed an intense and diffuse
staining of the cytoplasmatic membrane (Figure 4g). Higher-
magnification imaging depicts a clear punctate staining in glial
cells and diffuse membranous staining in the endothelial cells
lining tumor vessels (Figure S22). This links with the fact that
high hTRPV2 expression plays a role in angiogenesis36 and
tumor progression and associates with poor prognosis (Figure
4c−e). When we tested the prognostic value of hTRPV2
independent of the endothelial and microglia/macrophage
content, we confirmed that high hTRPV2 expression was still
significantly associated with prognosis in GBM (Cox propor-
tional-hazards regression p < 0.05) but not in low-grade glioma
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(p = 0.5). Altogether, our data and others’37 support GBM as a
candidate disease for treatment with hTRPV2 ligands,
including PL.
hTRPV2 Knockdown in Glioblastoma Cells Reduces
Sensitivity to PL and ROS Production. We first tested the
effect of PL in the viability of different GBM cell lines (U251,
U87, YKG1, and D8TRG/06MG) which express significant
amounts of hTRPV2 (Figure S23 and Table S5). These cell
lines were sensitive to PL (with IC50 values of 3.0, 6.6, 4.7, and
6.6 μM, respectively) after 72 h. Endothelial brain cells, which
also express hTRPV2, were sensitive to PL (IC50 = 1.6 μM),
while both microglia and astrocytes were less sensitive (IC50 >
10 μM) (Figure S23 and Table S5). Despite the high hTRPV2
expression found in the tumor microenvironment, the high
sensitivity to PL of cell lines expressing hTRPV2 and high
hTRPV2 dependency of CNS cell lines support the use of
GBM cell line models to study the relationship between
hTRPV2 and PL treatment. Our data show that cells
expressing hTRPV2 are sensitive to PL.
Figure 5. PL treatment affects ROS in hTRPV2 WT/KD U251 glioblastoma cells. (a) Transcriptomic (RNA-seq) analysis of PL effects on U251
TRPV2WT vs TRPVKD cells. The log2 fold changes between WT and KD cells show loss of PL activity in the knock-down. The numbers of
significant (padj < 0.05) genes are shown in the inset and are color annotated as indicated. (b) Log fold change correlation of genes between
TRPV2WT-PL-treated and TRPV2KD PL-treated U251 cells: genes are colored base on p-adjusted values as indicated in the inset, highlighting low
correlation between the two data sets. (c) Heatmap of reads (FPKM; expressed as a Z-score for each column, as indicated in the inset) of the top
50 significantly (padj < 0.05) differentially expressed genes in PL-treated TRPV2
WT and TRPV2KD U251 cells. (d) GSEA analysis of TRPV2WT
U251 cells treated with PL identified downregulation of the Hallmark gene-set “Oxidative Phosphorylation”, the gene-ontology “Mitochondrial
Envelope”, and the REACTOME “Translation” signatures. The plots show the running sum for the molecular signature database gene set within
the TRPV2WT/PL data including the maximum enrichment score and the leading-edge subset of enriched genes. (e) Determination of
mitochondrial potential using a fluorescent readout on a plate reader in PL-treated TRPV2WT and TRPV2KD U251 cells determined following
treatment with 10 μM of the dye JC-1. The ratio of green (λ = 530 ± 15 nm) and red/orange (λ = 590 ± 17.5 nm) fluorescence emission was
monitored after 48 h of PL treatment. Data represent the mean ± SD (n = 3). (f) ATP content determination using a luciferase-based ATP
detection assay following 48 h of PL treatment of TRPV2WT U251 cells. Data represent the mean ± SD (n = 5). (g) PL-induced ROS production is
TRPV2-dependent (n = 3, two-way ANOVA, Sidack’s multiple comparisons test **p = 0.0056, ****p < 0.001). Lower levels of ROS were
observed in the U251-TRPV2-KD cell line compared to the control cell line. Cellular ROS levels were measured after 1 h of PL treatment and
quantified with flow cytometry.
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To investigate the relationship between hTRPV2 and PL
treatment, we knocked down the expression of hTRPV2 (by
82 ± 12%, see Figure S24) in the U251 glioblastoma cells
(TRPV2KD) using the CRISPRi technology with dCas9-KRAB-
guide RNA plasmids.38 We found that the PL-induced effect
on viability is diminished when hTRPV2 expression is reduced
as shown in Figure S25a−c. TRPV2KD cells are 2-fold less
sensitive to the antiproliferative effects of PL (p = 0.0002,
unpaired t-test, Figure S25a). We then performed RNA-
sequencing analysis of U251 cells (TRPV2WT or TRPV2KD)
Figure 6. PL-loaded hydrogel scaffolds treat glioblastoma multiforme in vivo. (a) Experiment design showing the development of a biocompatible,
PL-loaded hydrogel suitable for local treatment of GBM. Experiment flow: U251 or U87-MG cells were injected intracranially (n = 5 per group). 8
days later, engraftment was confirmed with bioluminescent imaging. On day 9, PL-loaded or unloaded hydrogels were implanted. Tumor growth
was assessed at regular intervals by using bioluminescent imaging. (b) Histological image of a full mouse brain showing the hydrogel implant. (c)
Bioluminescent images of U251 and U87-MG xenograft mice treated with PL-loaded hydrogel (50 mg/kg) or unloaded hydrogel (control). Data
show that PL treatment successfully reduces tumor volume over a period of 21 days relative to the control, in which the tumor grows exponentially,
on both models of GBM. Tumor burden in mice treated with PL-loaded or unloaded hydrogel as measured by luciferase activity for (f) U251 and
(g) U87-MG models. Data are expressed as luciferase intensity (ROI on tumor site) as an indication of average tumor load in the control group at
each time point and represent group mean ± SEM. Data show a significant tumor burden difference between both groups (p ≤ 0.01, n = 5, Mann−
Whitney test) for (f) U251 and (g) U87-MG models. The Kaplan−Meier survival curve shows that mice treated with PL-loaded hydrogels have
significantly increased survival (p ≤ 0.001, log-rank Mantel-Cox test) relative to the control group for (h) U251 and (i) U87-MG models. The
experiment cutoff criteria included an increase in tumor size of around 500% relative to the original size measured for each mouse prior to hydrogel
implantation.
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treated with PL for 48 h. Principal component analysis
confirmed a stronger effect of PL-treatment in TRPV2WT cells,
with little separation between control and treatment conditions
in TRPV2KD cells (Figure S25d) confirming successful knock-
down of hTRPV2. Indeed, comparison of the fold changes
(PL-treated vs DMSO control) between TRPV2WT and
TRPV2KD cells identified only 100 genes that were significantly
(padj < 0.05) differentially expressed in the knockdown as
opposed to 7302 genes in the case of TRPV2WT cells (Figure
5a). This was further confirmed when comparing the fold
changes introduced by PL in TRPV2WT vs TRPV2KD cells,
which yielded high correlation to PL-treated TRPV2WT cells
only (Figure 5b). This shows that hTRPV2 knockdown in
glioblastoma cells reduces the sensitivity to PL and its induced
transcriptomic changes.
Inspection of significantly differentially expressed genes
upon PL treatment (padj < 0.05 and absolute fold-change >1.5)
identified several candidates linked to the electron transport
chain as well as in trafficking of ATP (including NDUFAB1,
NDUFAF7, KDM1A, and SLC25A5, Figure 5c). Indeed, gene-
set enrichment analysis (GSEA) highlighted the down-
regulation of oxidative phosphorylation as well as that of
several mitochondrial signatures, including that of the
mitochondrial envelope (Figure 5d, Figure S25e,f). To validate
this observation, we asked if the mitochondrial membrane
potential was compromised following treatment with PL.
Using the cationic dye JC-1 that changes its fluorescent signal
according with the energy state of the mitochondria, we
interrogated mitochondrial depolarization and found a
decrease in TRPV2WT U251 cells treated with PL, which was
not observed in TRPV2KD U251 cells (Figure 5e). In
agreement with this observation, ATP content was reduced
following PL treatment of U251 cells compared to a negative
control (Figure 5f).
PL is known to cause an increase in ROS, which ultimately
leads to cell death; however, the mechanism by which this
occurs has not previously been associated with TRPV2.39 We
found that U251-TRPV2-KD cells treated with PL accumulate
significantly less ROS relative to the control cells with normal
hTRPV2 expression levels (Figure 5g). This was further
supported by rescue studies using N-acetyl-L-cysteine (NAC).
NAC is commonly used to identify and test ROS inducers and
to inhibit ROS. Indeed, NAC was able to rescue U251 and
U87MG cell viability in the presence of PL (Figure S26). This
shows that NAC interfered with the activity of PL, further
supporting that PL affects mitochondrial dysfunction. This
implies that hTRPV2 plays a key role in the formation of ROS
in cells after PL treatment.
Taken together, these observations suggest that PL treat-
ment results in a TRPV2-dependent decrease of mitochondrial
membrane potential, which ultimately leads to the loss of
cellular ATP content. A recent study demonstrated that the
increase of cellular ROS by defective mitochondria links to loss
of translation40 in agreement with our transcriptomic analysis,
which identified strong downregulation of translational
signatures (Figure 5d).
Treatment of GBM via Sustained and Local Im-
planted PL-Scaffolds. Having obtained promising in vitro
functional assay data and established a mode of action in a
preclinical scenario, we next explored the therapeutic potential
of PL in a murine orthotopic xenograft model of GBM (Figure
6a,b). In our experience, PL was poorly soluble in
biocompatible formulations, and subcutaneous injections of
50 mg/kg resulted in toxicity with limited effects on
intracranial tumor growth (Figure S27). After considering
these results, we sought out a more effective mode for in vivo
drug delivery. Thus, we encapsulated PL in β-cyclodextrin (1:2
ratio), which dramatically improved its aqueous solubility.
Furthermore, to enhance therapeutic efficacy, we aspired to
eliminate the challenge of crossing the blood−brain barrier and
create a therapy suitable for local and sustained drug
administration. To this end, we devised implantable dextran-
dendrimer hydrogel scaffolds41−44 that were doped with PL
encapsulated in β-cyclodextrin. The cyclodextrin was used as a
“carrier” molecule to facilitate the dissolution of PL. β-
Cyclodextrin is a cyclic oligosaccharide, which consists of a
macrocyclic ring of 7 glucose subunits with a hydrophobic
interior and hydrophilic exterior that forms a complex with the
hydrophobic PL compound. This new material allowed us to
obtain a high concentration of PL at the tumor site. Moreover,
we minimized leakage of PL to healthy tissue by decorating the
hydrogel with aldehyde groups from oxidized dextran to
interact with cancer tissue amines and form adhesive bonds, as
previously reported.41−44 Profiling of our drug delivery system
showed a significant discharge of PL in the first 4 h followed by
steady release (3% of total) for at least 192 h under
physiological conditions (Figure S28). These data provide a
rationale to the in vitro toxicity experiments in which PL-doped
hydrogels were able to induce near complete cell death after
incubation with U251 cells for 24 h. The empty hydrogels did
not affect cell viability (Figure S29).
We proceeded to study the in vivo therapeutic efficacy of the
PL-doped hydrogels in two murine models of GBM (U251 and
U87-MG). The U251 malignant glioma cell line is known to
mimic the salient features of human GBM and displays
similarities at the genetic level.45,46 The U87 GBM model is
commonly used for assessing tumor angiogenesis and
antiangiogenic therapies in GBM.46,47 Tumors were induced
through direct injection of 2.5 × 105 U251-GFP-luc or 2.5 ×
105 U87-MG-luc cells into the brain of athymic nude mice
(Crl:NU(NCr)-Foxn1nu) via a burr hole 2.5 mm lateral and 1.5
mm posterior to bregma, above the right cerebrum. Nine days
post-tumor-injection, hydrogel scaffolds loaded with PL (50
mg/kg) were implanted in the supratentorial region directly
overlaying the area where the tumor was implanted in the right
hemisphere of the brain (Figure 6a,b). Empty hydrogel
implants, i.e., lacking the PL component, were used as
controls. Tumor volume was measured over time by
bioluminescence with Xenogen IVIS Lumina for 21 days
after hydrogel implantation (Figure 6c). The difference in
survival between the two groups was highly significant (p ≤
0.001, log-rank Mantel−Cox test) for both U251 (Figure 6d)
and U87 (Figure 6e) models. The mice exposed to PL-doped
hydrogel showed significant tumor size reduction at the end of
the study (n = 5, p ≤ 0.01 Mann−Whitney test) for both U251
(Figure 6f) and U87 (Figure 6g) models. To further
demonstrate the superiority of the local PL-hydrogel scaffold,
the efficacy of the local delivery was compared with systemic
(subcutaneous) injection of PL alone, both at a final
concentration of 50 mg/kg PL (Figure S27). We found that
although local administration of PL by means of a hydrogel
scaffold resulted in almost complete remission of the GBM
tumor, no effect on tumor reduction was attained following
systemic administration of the same concentration of PL.
These results provide substantial evidence that the hydrogel
scaffold is essential for higher therapeutic performance. In
ACS Central Science http://pubs.acs.org/journal/acscii Research Article
https://doi.org/10.1021/acscentsci.1c00070
ACS Cent. Sci. 2021, 7, 868−881
876
addition, no apparent signs of disease (not related to local
tumor growth) were seen in any of the animals for 21 days
after hydrogel implantation as indicated by the preservation of
steady body weight (Figure S30), pointing at both drug and
hydrogel biocompatibility. Histopathology of the liver, kidney,
lung, spleen, gastrointestinal tract, and heart showed no
significant changes or evidence of toxicity of PL. No evidence
of necrosis or other lesions (e.g., inflammation) was seen in the
brain, at the site of implantation (Figure S31).
Monitoring of tumor growth in the brain of PL-treated mice
showed delayed tumor progression (Figure 6d−g). Leptome-
ningeal dissemination was seen both through in vivo imaging,
as a second and less intense bioluminescence signal, dorsal and
caudal to the primary tumor and overlaying the posterior part
of the brain and spinal cord (Figure 6c), and also microscopi-
cally as tumor cells infiltrating and expanding the leptome-
ninges. Meningeal bioluminescence was seen in 60% (for U251
model) and 80% (for U87 model) of the mice in the control
groups, and only 20% for both U251 and U87 models in the
PL-treated group. PL-treated mice showed reduced tumor
growth at the site of injection, and tumor cells were rarely
found to infiltrate the meninges, as depicted in Figure 6c and
in Figure S32. This suggests that treatment with PL may
mitigate GBM proliferation and invasion. Immunohistochem-
istry showed that hTRPV2 is indeed expressed in the tumor
xenografts with higher expression in the PL-treated groups
(Figure S33). Altogether, the in vivo therapy using local
scaffolds to deliver PL was highly effective in both models of
GBM, presenting an almost complete tumor abrogation,
associated with a higher survival rate for as long as 80 days
for the U251 model and 70 days for U87 model.
PL Induces Selective ex Vivo Response in GBM
Patient-Derived Cells. Next, we evaluated the clinical
potential of PL using Pharmacoscopy, a technology that
utilizes high content automated microscopy to measure ex vivo
drug response directly in patient-derived cells.48,49 The
relevance of Pharmacoscopy has been previously demonstrated
in a clinical trial for aggressive hematological malignancies,
where it was used to identify the best treatment option for
patients, ultimately leading to better outcomes such as
increased progression-free-survival.48 Here, we tested PL ex
vivo drug responses in five surgically derived GBM patient
samples at three different drug concentrations. Freshly
dissociated cells that were initially cryopreserved before the
assay were incubated with PL, standard-of-care temozolomide
(TMZ), or DMSO as a negative control for 48 h. Then, to
identify potentially malignant cells, dissociated cells were
immunofluorescently labeled with the astrocyte marker S100B
as well as NESTIN (Figure 7), a marker for proliferating neural
progenitors’ cells, while CD45 (Figure S34) was included as a
counterstain to identify nonmalignant immune cells. In four
out of five tested patient samples (80%), PL induced a
significant decrease in the fraction of glioblastoma cells
(defined inclusively as either S100B or NESTIN positive
cells) at the highest tested concentration (50 μM) compared
to the negative control. Among these four responders, two
patient samples also responded to PL at lower concentrations.
The observed effect was “on-target”preferentially affecting
the putatively malignant cells and not the immune populations,
which was also reflected in our relative fraction readout.
Furthermore, when compared to TMZ, which is usually used
at higher in vitro concentrations than the ones tested, PL
Figure 7. Ex vivo drug response of GBM cells derived from five patients. In this experiment, the ZH prefix is followed by the unique patient ID (n =
5). Colored lines represent the tested drugs; piperlongumine (PL, red) and temozolomide (TMZ, gray), where the x-axis corresponds to the
concentrations tested (2, 20, 50 μM). The y-axis denotes fraction reduction of S100B+CD45− or NESTIN+CD45− cells identified by
immunofluorescence relative to the DMSO control (50 μM). Values plotted as mean ± SEM. Two-way ANOVA followed by Dunnett’s multiple
comparisons test was performed to calculate statistical significance (n = 4−5 replicate wells per treatment condition, n = 15 wells for DMSO
control). * padj < 0.05, ** padj < 0.01, *** padj < 0.001, **** padj < 0.0001.
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exerted a stronger effect within this range of low doses (Figure
7, Figure S34). Taken together, we provide promising evidence
of PL-induced selective drug response in tumor samples
derived from GBM patients. As our tested cohort is relatively
small, we hope future studies will further investigate the clinical
potential that PL might hold as a putative GBM therapy.
■ CONCLUSIONS
Statistical learning may be used to accelerate drug discovery
programs by prioritizing biochemical screens; such methods
ought to be generally applicable to molecules of synthetic and
natural origins. Under such a concept, our computer-driven
and disease agnostic approach constitutes also a viable
alternative to swiftly repurpose chemical matter and motivate
the development of innovative therapeutics. Here, by
dissecting the chemical features of PL, a hitherto unknown
relationship to hTRPV2 emerged. The mechanistic insights for
hTRPV2 have been rare, and its (patho)biological relevance is
largely unknown.50,51 To further our understanding of the
hTRPV2 mechanism of modulation by exogenous compounds,
we determined the PL-bound full-length rat TRPV2 structure
at an overall resolution of 3.5 Å and identified a transient,
allosteric binding site for PL along the S4−S5 linker of the
channel. A high-quality open state of TRPV2 has not yet been
resolved, so it is difficult to predict the exact mechanism of PL
inhibition of channel opening. However, the S4−S5 linker
plays a key role in channel opening across the entire TRP
channel family,52 which suggests that small molecule ligands
for this region modulate function. Calcium imaging data of
hTRPV2 mutants with the addition of PL further established
the importance of the Arg539 and Thr522 residues in TRPV2
channel’s calcium influx modulation and highlighted the role of
Arg539 against PL antagonism for TRPV2, consistent with the
cryo-EM structure.
Importantly, we establish that modulation of hTRPV2 by PL
affords a biologically relevant phenotype, in particular against
GBM in which hTRPV2 overexpression correlates with tumor
grade, and that the anticancer activity of PL is high in cell lines
with high hTRPV2 gene expression, which is required by CNS
cancer cell lines. Moreover, the CRISPRi-induced down-
regulation of hTRPV2 showed that GBM cells treated with PL
accumulate significantly less ROS relative to the control cells
and that knockdown of hTRPV2 also decreases sensitivity to
PL, which suggests the importance of TRPV2 for the
anticancer activity of PL. Indeed, with the presence of
damaged mitochondria (decreased mitochondrial membrane
potential and ATP content) in hTRPV2WT treated with PL,
increased ROS fold is expected in these cells. These increased
ROS levels impinge upon nuclear transcription of mitochon-
drial targeted proteins, as observed in the RNaseq analysis.
Finally, we also showed that hTRPV2 is a marker of poor
prognosis for GBM patients, and immunohistochemistry of
GBM tissues samples showed a strong correlation between
hTRPV2 overexpression and aggressiveness of the disease.
GBM remains an unmet medical need, with newly diagnosed
patients having a life expectancy of only 11−15 months (which
has not improved in the last 30 years), and new therapeutics
are urgently sought after. To that end, formulation of PL in a
hydrogel for sustained intracranial release afforded an effica-
cious GBM treatment in mice using two orthotopic GBM
models to harness an innovative mechanism of action. This
treatment resulted in a highly significant decrease in disease
progression and increase in survival, which greatly contributes
to the avoidance of relapses of GBM. Furthermore, using
Pharmacoscopy, we have demonstrated that PL shows
promising on-target ex vivo responses in surgically derived
GBM patient samples, further strengthening the clinical
potential and applicability of our findings. Altogether,
supported by functional and structural data, we showed the
power of computer perception and decision making from
complex data patterns and expect it to play an increasing role
in future drug discovery and in the success of GBM therapy.
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Antunes, Faculdade de Medicina, Universidade de Lisboa,
1649-028 Lisboa, Portugal
Ana Guerreiro − Instituto de Medicina Molecular Joaõ Lobo
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Lobo Antunes, Faculdade de Medicina, Universidade de
Lisboa, 1649-028 Lisboa, Portugal
Marta C. Marques − Instituto de Medicina Molecular Joaõ
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Antunes, Faculdade de Medicina, Universidade de Lisboa,
1649-028 Lisboa, Portugal
Maike Langini − Department of Pediatric Neuro-
Oncogenomics, DKFZ, Heidelberg 69120, Germany;
Department of Pediatric Neuro-Oncogenomics, DKTK, Essen
D-45147, Germany; Department of Pediatric Oncology,
Hematology, and Clinical Immunology, Medical Faculty,
University Hospital Düsseldorf, Düsseldorf 40225, Germany
Marc Remke − Department of Pediatric Neuro-Oncogenomics,
DKFZ, Heidelberg 69120, Germany; Department of
Pediatric Neuro-Oncogenomics, DKTK, Essen D-45147,
Germany; Department of Pediatric Oncology, Hematology,
and Clinical Immunology, Medical Faculty, University
Hospital Düsseldorf, Düsseldorf 40225, Germany
Rafael Roque − Laboratório de Neuropatologia, Hospital de
Santa Maria, Centro Hospitalar Universitário Lisboa Norte
(CHLN) EPE, 1649-028 Lisboa, Portugal
Tobias Weiss − Department of Neurology and Brain Tumour
Center, University Hospital Zürich and University of Zurich,
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Zürich, 8093 Zürich, Switzerland
Nuno L. Barbosa-Morais − Instituto de Medicina Molecular
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